News

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth, Palo Alto

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH

Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's ...

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk debuts Wegovy in South Africa as weight-loss drugs race gathers pace

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
Zacks.com on MSN2d

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

HSBC Raises Novo Nordisk (NVO) Price Target on Oral Semaglutide Market Share Boost

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...

As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...
BioSpace5d

A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...